Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (January 2023)
21 slides from Sona Nanotech's investor presentation, January 2023
Slide 1: Biocompatible Nanoparticle Technology: Unlocking Cancer Therapies & Rapid Diagnostics
Biocompatible Nanoparticle Technology Unlocking Cancer Therapies & Rapid Diagnostics sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Proposed Transformational Acquisition of Siva Therapeutics by Sona Nanotech
Proposed Transformational Acquisition* of Siva Therapeutics by Sona Nanotech: A mutual unlocking of value Deal Rationale Salient Deal Terms: Sona to acquire 100% of Siva for up to US$8.65 million • Sona gold nanorods key to THT success • 100% share consideration • Approval for THT could provide vali
Slide 4: Sona Nanotech at a Glance
Sona Nanotech at a BIOCOMPATIBLE GNR • Unique biocompatible proprietary gold nanorod manufacturing technology GOLD NANOROD TECHNOLOGY • Developer of novel lateral flow rapid tests • Key role in the advancement of photothermal medical therapies • Proposed transformative acquisition* provides a mutual
Slide 5: Sona's Platform Technology: Uniquely biocompatible gold nanorods (GNRs)
Sona’s Platform Technology: Uniquely biocompatible gold nanorods (GNRs) What are gold nanorods Limitations of other nanoparticles1 Sona’s GNR technology solution • Rod-shaped nanoparticles made of gold • Nanometer is one-billionth of a meter • Toxicity: Uniquely Biocompatible: • Sizes of 10 to 100 n
Slide 6: Two Areas of Strategic Focus
Two Areas of Strategic Focus* 01 THERAPIES 02 DIAGNOSTICS Rapid Diagnostic Tests (RDTs) THT Photothermal Cancer Therapy* • TBI (Concussion) CURRENT • Bovine TB Targeting therapeutic heat to tumors by injecting gold nanorods 3rd Party Test Development Services Targeted Drug Delivery Further Proprieta
Slide 7: Therapies
01 BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Sona Gold Nanorod ("GNR") Technology Uniquely biocompatible Unlocking of in-vivo medical applications potential GNR-Based Therapies sonanano.com 7 CSE: SONA | OTCQB: SNANF
Slide 8: Sona's GNR technology in Siva Therapeutics' Targeted Hyperthermia Therapy
Sona’s Proposed Sona’s GNR technology in Transformative Acquisition Siva Therapeutics’ Targeted ™ Current Cancer Treatments are risky, expensive and How does THT work? can do harm • Chemotherapy and radiotherapy are • Targets heat directly to the tumor Pioneered by • 24 years of experience non-selec
Slide 9: Targeted Hyperthermia Therapy
03 Targeted 02 SivaRods™ concentrate in Tumor is treated for 10 min solid tumors, 7-fold vs in non- with SivaLum™ infrared light tumor tissue set to same wavelength as the ™ nanorods Medical device with 04 Healthy cells withstand heat two components: 01 IR Light energy stress, up to 52°C, typical wi
Slide 10: THT photothermal cancer therapy using GNRs will address current treatment issues
THT photothermal cancer therapy using GNRs will address current treatment issues Siva’s THT “inside-out” heating maximizes efficacy and minimizes collateral damage Key Issue Using gold ‘in vivo’ is understood Current Approaches Siva THT Solution to be safe Laser Magnetic Fields Ultrasound Long-term
Slide 11: First THT Application: Colorectal Cancer Tumors
SivaLumTM 2.0 coupled to a sigmoidoscope, First THT Application: emitting infrared light Colorectal Cancer Tumors Why is THT uniquely suited for colorectal cancer treatment? Treatment o Alternatives diminish quality of life Benefits o Significant market o Outpatient procedure within current o Minima
Slide 12: Diagnostics
02 Lateral Flow Assays (LFA’s) BIOCOMPATIBLE as diagnostic tools are: Can provide rapid GNR • Simple results (eg. at-home GOLD NANOROD TECHNOLOGY • Fast pregnancy tests) at • Low-cost point-of-care • Rely on nanoparticles How could Sona’s GNRs make a difference? • Multiple test lines per unit GNR- B
Slide 13: Sona's Concussion Screening Test
Sona’s Concussion 10m “We estimate that between 1.1 and 1.9 million sports and Screening Test CONCUSSIONS PY 7 recreation related concussions occur annually in US children aged ≤18 years.” Prototype American Academy of Pediatrics8 Current Problems Sona’s Concussion Screening Solution Biomarkers Othe
Slide 14: Sona's Bovine Tuberculosis Test
Sona’s “With help from the NRC IRAP program and the collaboration with Bovine 17.7m our partners in the UK, we hope to offer farmers a more effective method for early detection of bovine TB than is Tuberculosis BOVINE TB TESTING EVENTS PY IN UK13 currently used to mitigate the spread of this debilit
Slide 15: Sona's next steps
Sona’s next steps: Pre-Clinical Financing GMP Production Certification SivaLumTM 2.0 Prototype Development Large Animal Studies Prepare and File FDA IDE Human Phase 1 Financing • Potential future clinical studies Human Pilot & Feasibility Study to provide multiple valuation Human Phase 2 Financing c
Slide 16: Product Development
Product Development Therapies Sona Therapeutics & Diagnostics Portfolio Targeted Hyperthermia Therapy Additional potential therapies Therapy/Diagnostic Patent Pre-clinical Phase Phase Phase Total Addressable with Siva Technologies* filed I II III Market Drug Delivery Targeted 135 000 The opportunity
Slide 17: Team
Team David Regan Len Pagliaro, PhD Darren Rowles Kulbir Singh PhD Robert Randall, CPA CEO President, Siva Therapeutics, Head of Diagnostics Co-Founder & Chief Financial Officer to be CSO, Sona Nanotech* Head of GNR R&D o Business and commercial o Prof. of Bioengineering & o 17 years' experience with
Slide 18: Directors
Directors James Megann Walter Strapps Neil Fraser Mark Lievonen Dr. Michael Gross Chair Director Director Director Director o 25 years of experience in venture o CEO and co-founder, Carver o Past-president of Medtronic Canada o Past-president of Sanofi Pasteur Biosciences Inc., a Khosla Ventures o L
Slide 19: GNR
info@sonanano.com Purdy’s Wharf Tower II Suite 2001 – 1969 Upper Water Street Halifax, Nova Scotia, Canada B3J 3R7 +1 902 442 0653 BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY David Regan CEO Sona Nanotech Inc. sonanano.com 19 CSE: SONA | OTCQB: SNANF
Slide 20: Sources in document
Sources in document 1. Mousavi SM, Hashemi SA, Mazraedoost S, Yousefi K, Gholami A, Behbudi G, Ramakrishna S, Omidifar N, Alizadeh A, Chiang WH. Multifunctional Gold Nanorod for Therapeutic Applications and Pharmaceutical Delivery Considering Cellular Metabolic Responses, Oxidative Stress and Cellul
Slide 21: Additional Reading
Additional Reading Gold Nanorods Traumatic Brain Injury Gold nanorods as contrast agents for biological imaging: optical properties, surface conjugation and photothermal Injury in review, 2020 edition: Spotlight on traumatic brain injuries across the life course - effects Traumatic Brain Injury–Rela